<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV)-induced immortalization of adult human B lymphocytes is suppressed by physiologic concentrations of human plasma <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Several inhibitory mechanisms appear to be operative </plain></SENT>
<SENT sid="2" pm="."><plain>First, <z:chebi fb="2" ids="39026">low density lipoproteins</z:chebi> (<z:chebi fb="15" ids="39026">LDL</z:chebi>) directly reduce the ability of EBV to transform human B cells </plain></SENT>
<SENT sid="3" pm="."><plain>Second, <z:chebi fb="15" ids="39026">LDL</z:chebi> as well as intermediate and <z:chebi fb="0" ids="39027">very low density lipoproteins</z:chebi> modulate early inductive events rendering the B cell refractory to transforming signals from EBV </plain></SENT>
<SENT sid="4" pm="."><plain>Third, <z:chebi fb="15" ids="39026">LDL</z:chebi> also selectively inhibit an EBV-inducible step that occurs within 24 h after transformation </plain></SENT>
<SENT sid="5" pm="."><plain>Finally, <z:chebi fb="0" ids="39027">very low density lipoproteins</z:chebi> can abrogate the ongoing, cellular proliferation of EBV-transformed, established B cell lines </plain></SENT>
<SENT sid="6" pm="."><plain>The plasma <z:chebi fb="2" ids="6495">lipoproteins</z:chebi> may therefore prevent the emergence of EBV-transformed malignant B cell clones in vivo </plain></SENT>
<SENT sid="7" pm="."><plain>Conceivably, on this basis, environmental and genetic influences on plasma <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> concentrations may affect the global distribution of Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, a lymphoid <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> putatively caused by EBV </plain></SENT>
</text></document>